

# DiaMedica to Present at the 14th Annual Noble Investor Conference

MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSXV:DMA) (OTCQB:DMCAF), today announced that Mr. Rick Pauls, its President and CEO, will present at Noble Capital Markets' Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on **Tuesday**, **January 30th at 01:30 pm EST - Studio 1** 

#### **About DiaMedica Therapeutics:**

DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica's shares are listed on the TSX Venture Exchange under the trading symbol "DMA" and on the OTCQB under the trading symbol "DMCAF".

DiaMedica's lead product candidate DM199, a recombinant (synthetic) form of the KLK1 protein, is in development for the treatment of neurological and kidney diseases.

For more information, please visit <u>www.diamedica.com</u>. Follow us on social media - <u>Twitter</u>, <u>LinkedIn</u>.

#### **About Noble Capital Markets, Inc.**

Noble Capital Markets, established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology, transportation & logistics and natural resources sectors. The company has offices in Boca Raton, New York and Boston and St. Louis. In addition to NobleCon - the annual multi-sector investor conference - and the Media, Finance & Investor Program - produced in partnership with the National Association of Broadcasters (NAB) and held each spring in Las Vegas - Noble hosts numerous "non-deal" corporate road shows throughout the year across the United States and Canada. Members: FINRA, SIPC, MSRB. <a href="https://www.noblecapitalmarkets.com">www.noblecapitalmarkets.com</a>

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.

#### For further information, please contact:

Paul Papi Vice President of Business Development DiaMedica Therapeutics Inc. Two Carlson Parkway, Suite 260 Minneapolis, MN Phone: (617) 899-5941

## info@diamedica.com

### Tweet this!



Source: DiaMedica Therapeutics Inc.